Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice
NCT ID: NCT01186133
Last Updated: 2025-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50000 participants
OBSERVATIONAL
2009-01-31
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DESyne in Routine Clinical Practice
NCT02039713
Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice
NCT05981911
Prospective Assessment of Efficacy and Safety of Drug Eluting Stents
NCT02313038
Comparison of Drug Eluting Balloon and Drug Eluting Stent
NCT01539603
Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus
NCT01293773
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DESSIAN
consecutive patients receiving CYPHER stent
No interventions assigned to this group
K-XIENCE
consecutive patients receiving Xience stent
No interventions assigned to this group
GENOUS
consecutive patients receiving GENOUS stent
No interventions assigned to this group
ELEMENT
consecutive patients receiving PROMUS-ELEMENT stent
No interventions assigned to this group
PRIME
consecutive patients receiving XIENCE-PRIME stent
No interventions assigned to this group
NOBORI
consecutive patients receiving NOBORI stent
No interventions assigned to this group
INTEGRITY
consecutive patients receiving RESOLUTE-INTEGRITY stent
No interventions assigned to this group
XPEDITION
consecutive patients receiving XIENCE-XPEDITION stent
No interventions assigned to this group
BIOMATRIX
consecutive patients receiving BIOMATRIX stent
No interventions assigned to this group
CILOTAX
consecutive patients receiving CILOTAX stent
No interventions assigned to this group
DEB
consecutive patients receiving Drug eluting balloon
No interventions assigned to this group
DESYNE
consecutive patients receiving DESYNE stent
No interventions assigned to this group
PREMIER
consecutive patients receiving PROMUS-PREMIER stent
No interventions assigned to this group
ORSIRO
consecutive patients receiving ORSIRO stent
No interventions assigned to this group
ONYX
consecutive patients receiving ONYX stent
No interventions assigned to this group
BVS
consecutive patients receiving Bioresorbable Vascular Scaffold
No interventions assigned to this group
BVS AMI
consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
No interventions assigned to this group
Ultimaster
consecutive patients receiving Ultimaster stent
No interventions assigned to this group
Synergy
consecutive patients receiving Synergy stent
No interventions assigned to this group
Biofreedom
consecutive patients receiving Biofreedom stent
No interventions assigned to this group
Firehawk
consecutive patients receiving Firehawk stent
No interventions assigned to this group
DESyne X2
consecutive patients receiving DESyne X2 stent
No interventions assigned to this group
Sierra
consecutive patients receiving Sierra stent
No interventions assigned to this group
Tansei
consecutive patients receiving Tansei stent
No interventions assigned to this group
Synergy XD and Synergy Megatron™
consecutive patients receiving Synergy XD or Synergy Megatron™ stent
No interventions assigned to this group
Xience-Skypoint
consecutive patients receiving Xience-Skypoint stent
No interventions assigned to this group
Coroflex ISAR NEO
consecutive patients receiving Coroflex ISAR NEO stent
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no clinical and lesion limitations
Exclusion Criteria
* terminal illness with life expectancy less than 1 year
* patients with cardiogenic shock
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CardioVascular Research Foundation, Korea
OTHER
Seung-Jung Park
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seung-Jung Park
MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seung-Jung Park, MD
Role: STUDY_CHAIR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korean centres
Multiple Locations, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Kim TO, Kang DY, Ahn JM, Kim MJ, Lee PH, Kim H, Choi Y, Lee J, Lee JM, Jo HH, Park YS, Lim SM, Park SJ, Park DW. Impact of Target Lesion Revascularization on Long-Term Mortality After Percutaneous Coronary Intervention for Left Main Disease. JACC Cardiovasc Interv. 2024 Jan 8;17(1):32-42. doi: 10.1016/j.jcin.2023.10.068.
Jeong YJ, Hyun J, Lee J, Kim JH, Yang Y, Choe K, Lee JS, Park H, Cho SC, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ; IRIS-DES Registry Investigators. Comparison of Contemporary Drug-Eluting Stents in Patients Undergoing Complex High-Risk Indicated Procedures. JACC Asia. 2022 Mar 1;2(2):182-193. doi: 10.1016/j.jacasi.2021.10.008. eCollection 2022 Apr.
Yang Y, Hyun J, Lee J, Kim JH, Lee JB, Kang DY, Lee PH, Ahn JM, Park DW, Park SJ; IRIS-DES Registry Investigators. Effectiveness and Safety of Contemporary Drug-Eluting Stents in Patients With Diabetes Mellitus. JACC Asia. 2021 Sep 21;1(2):173-184. doi: 10.1016/j.jacasi.2021.07.009. eCollection 2021 Sep.
Park S, Ahn JM, Kim TO, Park H, Cho SC, Kang DY, Lee PH, Park DW, Park SJ; IRIS-DES Registry Investigators. Incidence and Impact of Thrombocytopenia in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2020 Nov 1;134:55-61. doi: 10.1016/j.amjcard.2020.07.059. Epub 2020 Aug 16.
Park H, Ahn JM, Kang DY, Lee JB, Park S, Ko E, Cho SC, Lee PH, Park DW, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation. JACC Cardiovasc Interv. 2020 Jun 22;13(12):1403-1413. doi: 10.1016/j.jcin.2020.03.023. Epub 2020 May 27.
Lee CH, Ahn JM, Lee KS, Kang DY, Lee PH, Lee SW, Lee CW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Prevalence, predictors, prognostic significance, and effect of techniques on outcomes of coronary lesion calcification following implantation of drug-eluting stents: a patient-level pooled analysis of stent-specific, multicenter, prospective IRIS-DES registries. Coron Artery Dis. 2021 Jan;32(1):42-50. doi: 10.1097/MCA.0000000000000896.
Lee CH, Kang DY, Han M, Hur SH, Rha SW, Her SH, Seung KB, Kim KS, Lee PH, Ahn JM, Lee SW, Park SW, Park DW, Park SJ; IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol. 2019 May 1;282:17-23. doi: 10.1016/j.ijcard.2019.01.108. Epub 2019 Feb 2.
Lee PH, Kwon O, Ahn JM, Lee CH, Kang DY, Lee JB, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. J Am Coll Cardiol. 2018 Feb 27;71(8):832-841. doi: 10.1016/j.jacc.2017.12.032.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.